Neurocrine Biosciences
NBIX
#1383
Rank
NZ$21.69 B
Marketcap
$214.25
Share price
-0.13%
Change (1 day)
14.54%
Change (1 year)
Neurocrine Biosciences is an American biopharmaceutical company that develops treatments for neurological and endocrine-related diseases and disorders.

Neurocrine Biosciences (NBIX) - Total liabilities

Total liabilities on the balance sheet as of September 2024 : NZ$1.37 Billion

According to Neurocrine Biosciences 's latest financial reports the company's total liabilities are NZ$1.37 Billion. A companyโ€™s total liabilities is the sum of all current and non-current debts and obligations.

Neurocrine Biosciences - Total liabilities on balance sheet (from 2001 to 2024)

Total liabilities by year

Year Total liabilities Change
2023-12-31NZ$1.61 B54.85%
2022-12-31NZ$1.04 B1.79%
2021-12-31NZ$1.02 B21.26%
2020-12-31NZ$0.84 B-15.11%
2019-12-31NZ$0.99 B30.06%
2018-12-31NZ$0.76 B21.79%
2017-12-31NZ$0.62 B765.32%
2016-12-31NZ$72.48 M-1.43%
2015-12-31NZ$73.53 M67.82%
2014-12-31NZ$43.82 M5.09%
2013-12-31NZ$41.69 M-17.56%
2012-12-31NZ$50.57 M-49.58%
2011-12-31NZ$0.10 B-38.13%
2010-12-31NZ$0.16 B76.11%
2009-12-31NZ$92.05 M-34.38%
2008-12-31NZ$0.14 B-31.97%
2007-12-31NZ$0.20 B93.8%
2006-12-31NZ$0.10 B-21.82%
2005-12-31NZ$0.13 B-22.55%
2004-12-31NZ$0.17 B-30.28%
2003-12-31NZ$0.25 B211.94%
2002-12-31NZ$80.79 M-6.69%
2001-12-31NZ$86.59 M

Total liabilities for similar companies or competitors

Company Total liabilities differencediff. Country
NZ$1.47 B 7.29%๐Ÿ‡บ๐Ÿ‡ธ USA
NZ$13.13 B 853.78%๐Ÿ‡ฌ๐Ÿ‡ง UK
NZ$18.3 M-98.67%๐Ÿ‡บ๐Ÿ‡ธ USA
NZ$103.38 B 7,409.64%๐Ÿ‡บ๐Ÿ‡ธ USA
NZ$231.69 B 16,730.17%๐Ÿ‡บ๐Ÿ‡ธ USA
NZ$214.09 B 15,451.77%๐Ÿ‡บ๐Ÿ‡ธ USA
NZ$0.74 B-46.07%๐Ÿ‡บ๐Ÿ‡ธ USA
NZ$73.92 M-94.63%๐Ÿ‡บ๐Ÿ‡ธ USA